TAS-102 in patients with metastatic colorectal cancer refractory to standard therapies including regorafenib

被引：0
|
作者：
Kito, Yosuke [1 ]
Hamauchi, Satoshi [1 ]
Yamazaki, Kentaro [1 ]
Komori, Azusa [2 ]
Masuishi, Toshiki [2 ]
Taniguchi, Hiroya [2 ]
Mori, Keita [3 ]
Muro, Kei [2 ]
Yasui, Hirofumi [1 ]
机构：
[1] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Nagaizumi, Shizuoka, Japan
[2] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan
[3] Shizuoka Canc Ctr, Clin Res Ctr, Nagaizumi, Shizuoka, Japan
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O1 - 8 - 3
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies
    Sueda, Toshinori
    Sakai, Daisuke
    Kudo, Toshihiro
    Sugiura, Takashi
    Takahashi, Hidekazu
    Haraguchi, Naotsugu
    Nishimura, Junichi
    Hata, Taishi
    Hayashi, Taro
    Mizushima, Tsunekazu
    Doki, Yuichiro
    Mori, Masaki
    Satoh, Taroh
    ANTICANCER RESEARCH, 2016, 36 (08) : 4299 - 4306
  • [2] Efficacy and safety of regorafenib compared to TAS-102 for refractory metastatic colorectal cancer
    Abrahao, Ana Beatriz Kinupe
    Ko, Yoo-Joung
    Chan, Kelvin K.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] TAS-102 for metastatic refractory colorectal cancer
    Cleghorn, Sean
    LANCET ONCOLOGY, 2015, 16 (07): : E314 - E314
  • [4] COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB AND TAS-102 IN REFRACTORY METASTATIC COLORECTAL CANCER
    Cho, S. K.
    Hay, J. W.
    Barzi, A.
    VALUE IN HEALTH, 2018, 21 : S1 - S1
  • [5] A retrospective comparison between regorafenib and TAS-102 for refractory metastatic colorectal cancer.
    Masuishi, Toshiki
    Taniguchi, Hiroya
    Hamauchi, Satoshi
    Komori, Azusa
    Kito, Yosuke
    Mitani, Seiichiro
    Hasegawa, Hiroko
    Narita, Yukiya
    Kadowaki, Shigenori
    Ura, Takashi
    Ando, Masashi
    Mori, Keita
    Tajika, Masahiro
    Yasui, Hirofumi
    Muro, Kei
    Yamazaki, Kentaro
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [6] A meta-analysis comparing regorafenib with TAS-102 for treating refractory metastatic colorectal cancer
    Su, Guan-Li
    Wang, Yuan-Yuan
    Wang, Jin-Cheng
    Liu, Hao
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2020, 48 (07)
  • [7] Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
    Mayer, Robert J.
    Van Cutsem, Eric
    Falcone, Alfredo
    Yoshino, Takayuki
    Garcia-Carbonero, Rocio
    Mizunuma, Nobuyuki
    Yamazaki, Kentaro
    Shimada, Yasuhiro
    Tabernero, Josep
    Komatsu, Yoshito
    Sobrero, Alberto
    Boucher, Eveline
    Peeters, Marc
    Tran, Ben
    Lenz, Heinz-Josef
    Zaniboni, Alberto
    Hochster, Howard
    Cleary, James M.
    Prenen, Hans
    Benedetti, Fabio
    Mizuguchi, Hirokazu
    Makris, Lukas
    Ito, Masanobu
    Ohtsu, Atsushi
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (20): : 1909 - 1919
  • [8] Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States
    Cho, Sang Kyu
    Hay, Joel W.
    Barzi, Afsaneh
    CLINICAL COLORECTAL CANCER, 2018, 17 (04) : E751 - E761
  • [9] TAS-102 in metastatic colorectal cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2018, 19 (01): : E18 - E18
  • [10] A systematic review and network meta analysis of regorafenib and TAS-102 in refractory metastatic colorectal cancer.
    Sonbol, Mohamad Bassam
    Benkhadra, Raed
    Wang, Zhen
    Firwana, Belal
    Mody, Kabir
    Kasi, Pashtoon Murtaza
    Hubbard, Joleen Marie
    Murad, M. Hassan
    Ahn, Daniel H.
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
12345